210 related articles for article (PubMed ID: 29037225)
1. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
Li W; Cao Y; Xu J; Wang Y; Li W; Wang Q; Hu Z; Hao Y; Hu L; Sun Y; Xu G; Ao G
J Exp Clin Cancer Res; 2017 Oct; 36(1):144. PubMed ID: 29037225
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
3. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
4. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
5. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of miR-29a facilitates apoptosis of colorectal carcinoma cell SW480 and suppresses its Paclitaxel resistance.
Yuan LL; Li L; Liu JN; Mei J; Lei CJ
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5499-5507. PubMed ID: 30229821
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.
Wang L; Shi S; Guo Z; Zhang X; Han S; Yang A; Wen W; Zhu Q
PLoS One; 2013; 8(6):e65539. PubMed ID: 23762387
[TBL] [Abstract][Full Text] [Related]
8. COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
Xu G; Wang Y; Li W; Cao Y; Xu J; Hu Z; Hao Y; Hu L; Sun Y
Neoplasia; 2018 Apr; 20(4):324-334. PubMed ID: 29505957
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
[TBL] [Abstract][Full Text] [Related]
10. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.
Konsavage WM; Kyler SL; Rennoll SA; Jin G; Yochum GS
J Biol Chem; 2012 Apr; 287(15):11730-9. PubMed ID: 22337891
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
14. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
[TBL] [Abstract][Full Text] [Related]
15. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer.
Sun M; Song H; Wang S; Zhang C; Zheng L; Chen F; Shi D; Chen Y; Yang C; Xiang Z; Liu Q; Wei C; Xiong B
J Hematol Oncol; 2017 Mar; 10(1):79. PubMed ID: 28356122
[TBL] [Abstract][Full Text] [Related]
17. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer.
Song R; Gu D; Zhang L; Zhang X; Yu B; Liu B; Xie J
Mol Carcinog; 2018 Nov; 57(11):1608-1615. PubMed ID: 30074279
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
[TBL] [Abstract][Full Text] [Related]
20. The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
Zhang H; Ye Y; Bai Z; Wang S
Dig Dis Sci; 2008 Aug; 53(8):2195-203. PubMed ID: 18320325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
